ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Passage Bio Inc

Passage Bio Inc (PASG)

0.5949
0.0129
( 2.22% )
更新日時: 03:04:08

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
0.5949
買値
0.5949
売値
0.595
出来高
105,763
0.59 日の範囲 0.64455
0.54 52 週間の範囲 1.79
時価総額
前日終値
0.582
始値
0.613
最終取引時間
03:07:32
財務取引量
US$ 64,094
VWAP
0.606015
平均取引量 (3 か月)
234,574
発行済株式数
61,767,286
配当利回り
-
PER
-0.37
1 株当たり利益 (EPS)
-1.65
歳入
-
純利益
-102.06M

Passage Bio Inc について

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

セクター
Biological Pds,ex Diagnstics
業界
Biological Pds,ex Diagnstics
本社
Wilmington, Delaware, USA
設立
-
Passage Bio Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker PASG. The last closing price for Passage Bio was US$0.58. Over the last year, Passage Bio shares have traded in a share price range of US$ 0.54 to US$ 1.79.

Passage Bio currently has 61,767,286 shares in issue. The market capitalisation of Passage Bio is US$35.95 million. Passage Bio has a price to earnings ratio (PE ratio) of -0.37.

PASG 最新ニュース

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from...

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved...

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.0277-4.449084484420.62260.67990.5751833530.61980131CS
40.01382.374806401650.58110.67990.542094660.61727093CS
12-0.1622-21.42385418040.75710.84990.542345740.65691784CS
26-0.8651-59.25342465751.461.47650.542176210.78144085CS
52-0.0351-5.571428571430.631.790.543458840.96297588CS
156-8.1751-93.21664766258.778.850.543069871.8772351CS
260-21.6751-97.328693309422.2738.230.543037527.5043175CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MTEMMolecular Templates Inc
US$ 0.7681
(138.47%)
266.01M
AGFYAgrify Corporation
US$ 16.35
(56.76%)
1.11M
OMEROmeros Corporation
US$ 6.3934
(52.59%)
11.63M
QUBTQuantum Computing Inc
US$ 3.7601
(41.36%)
151.88M
IFRXInflaRx NV
US$ 2.2808
(33.38%)
1.21M
SOWGSow Good Inc
US$ 4.10
(-58.21%)
2M
NVCTNuvectis Pharma Inc
US$ 6.12
(-42.64%)
1.3M
TRNRInteractive Strength Inc
US$ 3.70
(-36.54%)
1.11M
VISLVislink Technologies Inc
US$ 4.41
(-33.18%)
82.7k
OPRXOptimizeRx Corporation
US$ 4.11
(-33.17%)
1.31M
ELABElevai Labs Inc
US$ 0.02645
(7.09%)
1.59B
XTIAXTI Aerospace Inc
US$ 0.0644
(12.59%)
324.57M
MTEMMolecular Templates Inc
US$ 0.7565
(134.86%)
266.19M
SVMHSRIVARU Holding Ltd
US$ 0.0279
(15.29%)
219.74M
QUBTQuantum Computing Inc
US$ 3.77
(41.73%)
147.61M

PASG Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock